source
- Roche remains bullish on giredestrant despite first-line trial setbackRoche's CEO Thomas Schinecker said the company still expects its investigational oral breast cancer therapy giredestrant to generate strong sales, potentially surpassing Herceptin. The optimism fo…
- Novartis' Lutathera radioligand therapy may soon face first generic challengerNovartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…